Bird & Bird's Venture Capital team advises Horizons Ventures on its investment in Owlstone Medical
Written By
Partner
UK
I am the International Head of Venture Capital at Bird & Bird, focusing on domestic and international corporate transactions for emerging and high-growth companies and the investors in and lenders to those companies.
Related
Practices
Sectors
Countries
Bird & Bird’s London Corporate team acted for global investor, Horizons Ventures, in its participation in Owlstone Medical’s $58M Series D fundraise. The round was led by Horizons Ventures, a Hong-Kong based VC firm which focuses on disruptive and tech-focussed start-ups.
Owlstone Medical, based in Cambridge UK, is the global leader in breath biopsy for applications in early disease detection and precision medicine. Horizons Ventures now takes a seat on Owlstone Medical’s Board and is joined by select existing and new investors from Asia, the Middle East and the United States.
The team was led by Corporate partner, Struan Penwarden who was assisted by Arif Saleem (Senior Associate) and Greg Turton (Associate).
Struan Penwarden, head of Venture Capital at Bird & Bird said: “We are delighted to have assisted Horizon Ventures on this significant investment into Owlstone Medical, having previously acted for them on the Series C round. The Series D round was an international transaction and the financing will accelerate the development of Owlstone Medical’s innovative technology in the MedTech field. This is a prime example of Bird & Bird’s Venture Capital, Tech and Life Science capabilities.”
Latest insights
More Insights
Kingdom of Saudi Arabia: Imminent deadline for digital content platforms to comply with new KSA regulations
Oct 03 2024
Navigating the Complex Landscape of Merger Control and Foreign Direct Investment in Life Sciences in the EU and UK
Oct 01 2024
Long-awaited German judgment by the District Court of Hamburg (Kneschke v. LAION) on the text and data mining exception(s)
Oct 01 2024